SURISimplify Propel Opportunities ETF
Seeks long-term capital appreciation.
By Simplify Asset Management · Launched 2023
Annual Cost
2.56%
#5,822 of 5,861 · expensive
Fund Size
$77M
#3,231 of 5,861 · mid-size
Return (1Y)Goal
+40.9%
Track Record
3 years
#2,857 of 5,861 · seasoned
Performance
Total-return NAV · USDGrowth of $10,000
$14,077+40.8%
Total-return NAV, USD. Net of fund fees, before tax.
What's inside
How Beacon categorizes this fundWhat it actually holds
By weightConcentration
Top 10 holdings = 163.9% of fundconcentrated
United States Treasury Bills
92.9%
Plains GP Holdings LP
44.5%
Achieve Life Science Inc
5.0%
Phathom Pharmaceuticals Inc
4.2%
Delcath Systems Inc.
3.5%
Abeona Therapeutics Inc.
3.2%
Celldex Therapeutics Inc.
3.2%
Milestone Pharmaceuticals Inc
2.6%
Oculis Holding AG
2.6%
LeonaBio Inc.
2.2%
Asset allocation
Stocks
97.3%
Bonds
77.9%
Risk profile
Last 12 months · Sharpe & Sortino need 3+ yearsVolatility (1Y)
22.2%High
Year-on-year price swings
Max drawdown
-47.7%Severe
Worst peak-to-trough loss
Sharpe (3Y)
0.35Below average
Sortino (3Y)
0.49Moderate downside risk
Bond profile
Avg maturity
9.9 years
Credit ratings
US Government
76.8%
AAA
19.1%
AA
29.3%
A
27.8%
BBB
23.7%
Other
0.1%
Listing
- Exchange
- NYSE Arca
Full fund details
- Objective
- Seeks long-term capital appreciation.
- Strategy
- Actively manages a portfolio concentrated in small to medium capitalization companies in the healthcare sector, including biotechnology and pharmaceuticals, while also investing in energy-related securities. The strategy aims for long-term capital appreciation through fundamental analysis and opportunistic multi-asset investments.
- Inception date
- February 7, 2023
- Fund family
- Simplify Asset Management
Similar funds
Same asset class, closest by strategy & exposureWhat's next?
You've looked at SURI. Save it to your watchlist to weigh it against other funds, then turn your shortlist into a portfolio.
Data updated on 2026-08-04